Therapeutic interchange vs therapeutic substitution: how hospital P&T committees run a protocol

The short answer: a therapeutic interchange is the exchange of a prescribed drug for a different chemical entity that is expected to produce a comparable therapeutic result, carried out under a protocol the pharmacy and therapeutics committee has approved in advance. It is not the same as generic substitution, which swaps a brand product for a chemically identical generic. Interchange crosses molecules; generic substitution does not. That difference is why one is routine pharmacy practice and the other needs a written, committee-approved protocol behind it.

Most of the confusion around this topic comes from three terms being used as if they were interchangeable when they describe different things with different legal footing. Here is the version that survives a challenge in a formulary meeting.

What is a therapeutic interchange?

A therapeutic interchange substitutes one drug for another within the same therapeutic class, where the two are considered clinically comparable for the indication in question but are not the same molecule. Swapping one proton pump inhibitor for the one your hospital stocks is a therapeutic interchange. So is converting a patient admitted on one statin to the formulary statin at an equivalent intensity.

The defining feature is not the swap itself but the authority behind it. In US hospitals the interchange happens under a protocol that the pharmacy and therapeutics committee has written, reviewed and approved, usually with medical staff endorsement. That protocol names the drugs in scope, the conversion, the exclusions, and what the pharmacist does when a patient does not fit. Without that document, a pharmacist changing a prescriber's drug choice is not running an interchange, they are making an unauthorized change.

Two terms describe roughly this same activity. "Therapeutic interchange" is the phrase used in most US hospital pharmacy and health-system documentation. "Therapeutic substitution" is the more general term and shows up more often outside institutional practice, sometimes with a slightly negative connotation because it has historically been used to describe payer-driven swaps. In day-to-day hospital use they point at the same process.

What is the difference between therapeutic substitution and generic substitution?

This is the distinction that matters most, and it is the one people get wrong. Generic substitution replaces a brand-name product with a generic containing the same active ingredient at the same strength and dosage form, where the FDA has rated the two as therapeutically equivalent. The molecule does not change. Every state permits pharmacists to do this, with the specifics of consent, notification and prescriber override set by state law.

Therapeutic substitution replaces the drug with a different molecule. Because the chemical entity changes, so does the risk profile: different pharmacokinetics, different interaction profile, different adverse effects, sometimes different dosing intervals. That is why it cannot ride on generic substitution law. It requires either the prescriber's authorization for that patient or a protocol the institution approved in advance on the prescriber's behalf.

What is the difference between a therapeutic equivalent and a therapeutic alternative?

A therapeutic equivalent is a specific regulatory designation. The FDA assigns it to products containing the same active ingredient that are both pharmaceutically equivalent and bioequivalent, and it is what an AB rating in the Orange Book means. It is a statement about two versions of one drug.

A therapeutic alternative is a clinical judgment, not a regulatory rating. It means a different drug expected to produce a similar outcome for the same indication. Two agents can be sensible therapeutic alternatives and share no regulatory relationship whatsoever. Therapeutic interchange operates entirely in this second category, which is precisely why it needs local clinical governance rather than a federal rating to justify it.

Who approves a therapeutic interchange protocol?

The pharmacy and therapeutics committee owns it. In a typical US health system the sequence runs: a pharmacist or a clinical service proposes the interchange, usually because the formulary carries one agent in a class and admissions regularly arrive on others; drug information pharmacists assemble the evidence comparing the agents for the indications in scope; the committee reviews the proposal along with the exclusions and the conversion; and the medical staff structure endorses it so that the protocol carries prescriber authority rather than overriding it.

The evidence review is the part that takes real work, because the committee has to be satisfied the agents are genuinely comparable for the specific uses in scope, not merely members of the same class. Class membership is a weak argument on its own. Agents within a class differ in interaction profile, renal handling, and the indications actually studied, and the drug information pharmacist's job is to surface those differences before the committee votes rather than after a patient is switched.

Once approved, the protocol is a controlled document. It needs a review date, a named owner, a record of what the committee approved and when, and a way to show an auditor or a surveyor that staff were working from the current version. Health systems that run many of these end up managing a sizable library of them, and the same discipline that applies to any other policy that has to stay documented and auditable applies here: an out-of-date protocol still sitting in the workflow is a genuine safety problem, not a paperwork one.

What does an automatic therapeutic substitution policy include?

"Automatic" describes a protocol the pharmacist may act on without contacting the prescriber for each individual patient, because the authorization was granted in advance at committee level. A workable one specifies all of the following:

• Scope. Which drugs may be interchanged, for which indications, and the formulary agent they convert to.
• Conversion. The dose relationship between the agents, including how rounding is handled and what happens with non-standard strengths.
• Exclusions. The patients the protocol does not touch. Transplant, oncology, pediatric and obstetric populations are commonly carved out, as are patients stabilized on a specific agent after documented failure of alternatives.
• Prescriber opt-out. How a prescriber marks an order as not eligible, which is what keeps the protocol an authorization rather than an override.
• Documentation. What the pharmacist records, and how the change is communicated to the care team and carried into discharge.
• Discharge handling. Whether the patient goes home on the formulary agent or reverts, and who reconciles it. This is where interchange protocols most often go wrong.

That last point deserves emphasis. An inpatient interchange is contained by the fact that the patient is being monitored. The risk escalates at discharge, when a swap made for stocking reasons can silently become a permanent change to the outpatient regimen, sometimes at a cost the patient cannot sustain and sometimes duplicating a drug they still have at home.

Therapeutic interchange examples

These are classes where US hospitals commonly maintain protocols. They are illustrative of where the practice is established, not a recommendation: what is appropriate at your institution is whatever your own committee has reviewed and approved.

The statin row is the one that catches teams out. Converting between statins at matched intensity is arithmetic, but the interaction profiles across the class are not equivalent at all: some are metabolized through CYP3A4 and some are not, so an interchange can quietly create or resolve an interaction with a drug the patient was already taking. Our reference page on statin drug interactions covers which agents avoid that pathway.

Which drug reference supports an interchange decision?

Building a protocol is drug information work, and it needs a reference deep enough to defend a comparison between molecules rather than just look up a dose. In practice that means a compendium. Pharmacists assembling the evidence for a committee typically work from a drug compendium for the monograph-level detail, and reach for a disease reference when the question is whether the agents are comparable for a specific indication at all.

Those are genuinely different resources, which is why many health systems license both. Our comparison of UpToDate versus Micromedex works through that split directly, since one is a disease reference and the other is a drug compendium, and neither vendor publishes a price. If your question is narrower and specifically about drug content depth, Lexicomp versus Micromedex is the closer comparison, and Epocrates versus Lexicomp covers what the lighter point-of-care tools can and cannot support in a large hospital. The contract side, including the user thresholds that push an institution onto an enterprise agreement, is in our guide to institutional and group licensing.

Where the real risk sits after the protocol is approved

A well-written protocol handles the drug pair. What it cannot handle is the patient in front of you. The interchange is approved at class level, but the patient arrives with their own medication list, their own kidney function and their own allergy history, and the agent your formulary stocks may interact with something the original agent did not. Protocols carry exclusions for exactly this reason, and the exclusion only works if somebody notices it applies.

That check is the narrow job Prescriber.io is built for. You enter the drug or the scenario once and it checks for drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments, and suggests guideline-based alternatives, together, with a cited source on each flag so you can confirm it. It is decision-support, not autonomous prescribing, and it does not replace the compendium your committee builds protocols from. Every flag is a prompt for a licensed clinician who reviews it, verifies against official sources, and signs.